Tag:

AMRI

Latest Headlines

Latest Headlines

AMRI inks a 10-year NIH deal with $37M on the line

In-transition drug developer AMRI has won a 10-year contract with the National Institutes of Health to help develop and manufacture neurological drugs.

AMRI buys more manufacturing capacity with deal for two Aptuit facilities

AMRI has extended a buying streak to build up its contract manufacturing capabilities, adding to its injectable drug operations in the process. The New York-based company will lay out $60 million to buy two facilities from drug development specialist Aptuit.

AMRI spends $60M to beef up its manufacturing heft

AMRI, on the mend after a rough quarter, is laying out $60 million to expand its manufacturing footprint, agreeing to buy a couple of outposts from service provider Aptuit.

AMRI gets its desert branch back online after a profit-sapping outage

After a weather-related shutdown at a New Mexico facility helped tank its quarterly earnings, AMRI has rectified the issue, bringing its plant back online as it works to get back on the path to growth.

Plant power outage zaps the juice from AMRI's earnings

Earlier this year, AMRI paid $110 million for injectable drug specialist Oso Biopharmaceuticals Manufacturing, expecting to make some extra money in its contract manufacturing operations. Instead, a power loss at that company's facility in New Mexico was a big factor in it reporting a loss in the last quarter.

AMRI tanks on disappointing sales and a dimmer outlook

Contract drug developer AMRI watched its shares plummet after underperforming in the third quarter, an earnings miss the company blamed on declining demand, spiking costs and bad weather in the desert.

AMRI buys into proteomics to expand its discovery services

Contract drug developer AMRI is expanding its platform to include protein R&D, investing in a market the company expects to boom over the coming years.

AMRI swings to revenue growth amid a transitional year

Contract drug developer AMRI posted a 15% boost in its quarterly revenue, using M&A and manufacturing demand to help wean it off royalty cash.

AMRI eyes a big year after completing another buyout

Contract developer AMRI has closed its $110 million acquisition of drug manufacturer Oso Biopharmaceuticals, its second deal this year and one the company believes will help pad its annual revenue.

AMRI finishes second manufacturing buy in 3 months

AMRI is building up its contract manufacturing operations and has completed a $110 million deal for Oso Biopharmaceuticals Manufacturing to add that company's expertise in complex injectable drug products to its stable.